Stefano Fanti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7892435/publications.pdf

Version: 2024-02-01

343 papers	19,403 citations	10389 72 h-index	14208 128 g-index
356 all docs	356 docs citations	356 times ranked	14021 citing authors

#	Article	IF	Citations
1	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€"2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	1.9	1,545
2	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€"2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	1.9	633
3	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589
4	Prospective Comparison of ¹⁸F-Fluoromethylcholine Versus ⁶⁸Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Journal of Nuclear Medicine, 2015, 56, 1185-1190.	5.0	516
5	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
6	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood, 2011, 118, 5989-5995.	1.4	445
7	Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2004-2010.	6.4	394
8	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 2017, 105, 212-244.	2.5	325
9	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18Fâ€"DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601.	6.4	319
10	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 2007, 92, 50-55.	3.5	318
11	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. European Urology, 2019, 75, 967-987.	1.9	278
12	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
13	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
14	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1431-1438.	6.4	254
15	68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1284-1294.	6.4	234
16	11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. European Urology, 2008, 54, 392-401.	1.9	232
17	Influence of Trigger PSA and PSA Kinetics on ¹¹C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2009, 50, 1394-1400.	5.0	230
18	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92.	1.9	230

#	Article	IF	Citations
19	Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 67-77.	6.4	229
20	⁶⁸Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 669-673.	5.0	227
21	18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1601-1610.	6.4	204
22	PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 55-69.	6.4	200
23	FDG PET/CT for assessing tumour response to immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 238-250.	6.4	194
24	Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and¹¹C-Choline PET/CT. Radiology, 2007, 244, 797-806.	7.3	193
25	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
26	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. European Urology, 2016, 70, 161-175.	1.9	184
27	Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine, 2005, 46, 1642-9.	5.0	178
28	The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. European Urology, 2011, 59, 51-60.	1.9	177
29	Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5Âng/ml?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 55-63.	6.4	166
30	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.	0.4	165
31	Standardized Uptake Values of ⁶⁸Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 353-359.	5.0	161
32	The Impact of Somatostatin Receptorâ€"Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 2017, 58, 756-761.	5.0	158
33	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	1.9	151
34	Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1396-1403.	6.4	143
35	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4384-4390.	7.0	140
36	A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. European Urology Oncology, 2019, 2, 47-76.	5.4	140

#	Article	IF	Citations
37	Anti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. Journal of Nuclear Medicine, 2014, 55, 1986-1992.	5.0	138
38	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 525-531.	6.4	135
39	PET/CT imaging in different types of lung cancer: An overview. European Journal of Radiology, 2012, 81, 988-1001.	2.6	132
40	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
41	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus, 2020, 6, 231-234.	3.1	131
42	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	2.8	120
43	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	6.4	119
44	Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging¹¹C-Choline PET/CT Scan Before Salvage Radiation Therapy?. Journal of Nuclear Medicine, 2014, 55, 1424-1429.	5.0	118
45	18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse. Clinical Nuclear Medicine, 2015, 40, e386-e391.	1.3	118
46	Current status of theranostics in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 471-495.	6.4	115
47	68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 52-60.	6.4	112
48	Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 57-71.	6.4	111
49	Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 11-17.	6.4	109
50	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84.	1.0	109
51	68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 722-727.	6.4	107
52	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	1.6	107
53	Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. European Journal of Radiology, 2012, 81, e893-e896.	2.6	106
54	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. European Urology, 2020, 77, 614-627.	1.9	101

#	Article	IF	Citations
55	11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World Journal of Surgical Oncology, 2007, 5, 68.	1.9	97
56	68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	6.4	96
57	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over 712-719.	6.4	95
58	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	6.4	92
59	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	6.4	91
60	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	10.7	90
61	68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nuclear Medicine Communications, 2009, 30, 281-286.	1.1	89
62	Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2222-2231.	6.4	86
63	Standardization of ¹⁸F-FDGâ€“PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	1.6	85
64	Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomedicine and Pharmacotherapy, 2008, 62, 667-671.	5.6	82
65	Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. Journal of Nuclear Medicine, 2020, 61, 678-682.	5.0	81
66	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncology, The, 2008, 9, 352-358.	10.7	80
67	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	6.4	79
68	11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1971-1979.	6.4	79
69	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 596-604.	5.0	79
70	Prognostic Value of ⁶⁸Ga-DOTANOC PET/CT SUV_{max} in Patients with Neuroendocrine Tumors of the Pancreas. Journal of Nuclear Medicine, 2015, 56, 1843-1848.	5.0	78
71	11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 84-91.	6.4	77
72	FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1538-1544.	6.4	76

#	Article	IF	Citations
73	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. Clinical Cancer Research, 2012, 18, 796-807.	7.0	74
74	68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 31-39.	6.4	74
75	Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Annals of Nuclear Medicine, 2010, 24, 485-492.	2.2	70
76	18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. Clinical Genitourinary Cancer, 2014, 12, 106-110.	1.9	68
77	Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1985-1989.	6.4	67
78	18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis. Clinical Nuclear Medicine, 2013, 38, e171-e177.	1.3	66
79	The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). Clinical Nuclear Medicine, 2013, 38, e74-e79.	1.3	65
80	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. Journal of Nuclear Medicine, 2020, 61, 626-629.	5.0	65
81	18F-DOPA PET/CT in Neuroblastoma. Clinical Nuclear Medicine, 2012, 37, e73-e78.	1.3	63
82	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1190-1196.	6.4	63
83	The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL. Clinical Nuclear Medicine, 2013, 38, e342-e345.	1.3	63
84	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2014, 55, 1936-1944.	5.0	63
85	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematology,the, 2016, 3, e467-e479.	4.6	63
86	Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2014, 55, 1591-1597.	5.0	62
87	PET Tracers Beyond FDG in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 507-521.	4.6	62
88	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-239.	3.1	62
89	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
90	Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. Diagnostic and Interventional Radiology, 2016, 22, 400-406.	1.5	61

#	Article	IF	Citations
91	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. Clinical Cancer Research, 2010, 16, 3998-4004.	7.0	60
92	Midtreatment ¹⁸Fâ€fluorodeoxyglucose positronâ€emission tomography in aggressive nonâ€Hodgkin lymphoma. Cancer, 2011, 117, 1010-1018.	4.1	60
93	18F-FDG PET/CT impact on testicular tumours clinical management. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 668-673.	6.4	60
94	Imaging the Folate Receptor on Cancer Cells with ^{99m}Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging. Journal of Nuclear Medicine, 2014, 55, 701-704.	5.0	59
95	Incidence of Increased ⁶⁸Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. Journal of Nuclear Medicine, 2011, 52, 886-890.	5.0	57
96	Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. Nanomedicine, 2015, 10, 3483-3494.	3.3	57
97	Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 136-146.	6.4	56
98	Choline PET/CT for prostate cancer: Main clinical applications. European Journal of Radiology, 2011, 80, e50-e56.	2.6	55
99	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leukemia and Lymphoma, 2006, 47, 2096-2101.	1.3	54
100	11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 878-886.	6.4	54
101	Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. Endocrine Pathology, 2016, 27, 55-64.	9.0	52
102	The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 215-223.	6.4	52
103	Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. Journal of Nuclear Medicine, 2020, 61, 1278-1283.	5.0	51
104	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
105	11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 149-155.	6.4	49
106	Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1046-1056.	6.4	49
107	Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1671-1678.	6.4	47
108	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	7.3	46

#	Article	IF	Citations
109	The Use of Gallium-68 Labeled Somatostatin Receptors in PET/CT Imaging. PET Clinics, 2014, 9, 323-329.	3.0	45
110	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 194-205.	6.4	45
111	Pulmonary artery intimal sarcoma. Problems in the differential diagnosis. Radiologia Medica, 2013, 118, 1259-1268.	7.7	42
112	¹¹C- or ¹⁸F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 43S-48S.	5.0	42
113	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
114	Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. JACC: Cardiovascular Imaging, 2020, 13, 2400-2411.	5.3	40
115	Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer. Clinical Nuclear Medicine, 2014, 39, e308-e312.	1.3	39
116	11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, e265-e270.	1.3	39
117	[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imagingâ€"version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 579-591.	6.4	39
118	Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2139-2146.	6.4	38
119	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 273-282.	5.4	37
120	Usefulness of 64Cu-ATSM in Head and Neck Cancer. Clinical Nuclear Medicine, 2014, 39, e59-e63.	1.3	36
121	Imaging for Prostate Cancer Recurrence. European Urology Focus, 2016, 2, 139-150.	3.1	36
122	Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced nonâ€"small cell lung cancer treated with first-line pembrolizumab. European Journal of Cancer, 2021, 150, 99-107.	2.8	36
123	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. Journal of Nuclear Medicine, 2016, 57, 61S-66S.	5.0	35
124	Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1278-1283.	6.4	34
125	The Evolving Role of Prostate-Specific Membrane Antigenâ€"Based Diagnostics and Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 321-330.	3.8	33
126	Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. Clinical Nuclear Medicine, 2014, 39, e320-e324.	1.3	32

#	Article	IF	Citations
127	Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. BMC Research Notes, 2014, 7, 32.	1.4	32
128	68Ga-DOTA-peptides in the Diagnosis of NET. PET Clinics, 2014, 9, 37-42.	3.0	32
129	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 2016, 41, e87-e92.	1.3	32
130	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749.	2.1	31
131	The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1712-1720.	6.4	31
132	Therapy assessment in prostate cancer using choline and PSMA PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 78-83.	6.4	31
133	68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 46-48.	6.4	30
134	11C-Choline PET/CT and Bladder Cancer. Clinical Nuclear Medicine, 2015, 40, e124-e128.	1.3	30
135	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large Bâ€cell lymphoma: experience on 74 patients. Hematological Oncology, 2015, 33, 145-150.	1.7	30
136	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. American Journal of Roentgenology, 2017, 209, 152-158.	2.2	29
137	Comparison of CT and PET/CT for biopsy guidance in oncological patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1269-1274.	6.4	29
138	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. European Urology Oncology, 2019, 2, 152-162.	5.4	29
139	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. Tumori, 2009, 95, 382-384.	1.1	28
140	Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning. Clinical Nuclear Medicine, 2014, 39, e367-e374.	1.3	28
141	Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2018, 28, 575-580.	2.5	28
142	Radioguided surgery with Î² radiation: a novel application with Ga68. Scientific Reports, 2018, 8, 16171.	3.3	28
143	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879356.	3.2	28
144	Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). Journal of Nuclear Medicine, 2022, 63, 240-247.	5.0	28

#	Article	IF	Citations
145	Extranodal marginal zone Bâ€cell lymphoma of the lung: experience with fludarabine and mitoxantroneâ€containing regimens. Hematological Oncology, 2013, 31, 183-188.	1.7	27
146	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
147	FDG small animal PET permits early detection of malignant cells in a xenograft murine model. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 755-762.	6.4	25
148	Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1293-1300.	6.4	25
149	Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients. Nuclear Medicine Communications, 2015, 36, 1065-1075.	1.1	25
150	Evaluation of Prostate Cancer with ¹¹C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. Journal of Nuclear Medicine, 2016, 57, 49S-54S.	5.0	25
151	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 370-395.	5.4	25
152	Epithelial and Mesenchymal Tumor Compartments Exhibit In Vivo Complementary Patterns of Vascular Perfusion and Glucose Metabolism. Neoplasia, 2007, 9, 900-908.	5.3	24
153	GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer, 2012, 12, 586.	2.6	24
154	Novel Structured Reporting Systems for Theranostic Radiotracers. Journal of Nuclear Medicine, 2019, 60, 577-584.	5.0	24
155	11C-Choline PET/CT for Restaging of Bladder Cancer. Clinical Nuclear Medicine, 2015, 40, e1-e5.	1.3	23
156	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399.	2.1	23
157	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€”A Multicenter Retrospective Study. Cancers, 2019, 11, 700.	3.7	23
158	C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. Clinical Nuclear Medicine, 2009, 34, 659-665.	1.3	21
159	11C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. Molecular Metabolism, 2013, 2, 153-160.	6.5	21
160	Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. Cancer Biology and Therapy, 2014, 15, 1219-1225.	3.4	21
161	New aspects of molecular imaging in prostate cancer. Methods, 2017, 130, 36-41.	3.8	21
162	How does ⁶⁸Gaâ€prostateâ€specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. International Journal of Urology, 2019, 26, 804-811.	1.0	21

#	Article	IF	Citations
163	Evaluation of an Automated Module Synthesis and a Sterile Cold Kitâ€“Based Preparation of ⁶⁸Ga-PSMA-11 in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 716-722.	5.0	20
164	Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSAâ€‰<â€‰1Âng/ml external validation on a single institution database. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2100-2105.	6.4	20
165	New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2022, 23, 703-720.	3.0	20
166	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. European Urology Oncology, 2022, 5, 530-536.	5.4	20
167	First Case of ¹⁸F-FACBC PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse after Radical Prostatectomy for Prostate Cancer and Negative ¹¹C-Choline PET/CT: New Imaging Techniques May Expand Pioneering Approaches. Urologia Internationalis, 2014, 92, 242-245.	1.3	19
168	Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 305-312.e1.	1.9	19
169	Molecular Imaging and Theranosticsâ€”A Multidisciplinary Approach. Seminars in Nuclear Medicine, 2019, 49, 247-254.	4.6	19
170	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	5.0	19
171	Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 7-18.	0.7	19
172	Cardiac resynchronization therapy and cardiac sympathetic function. European Journal of Clinical Investigation, 2015, 45, 792-799.	3.4	18
173	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. Cancers, 2021, 13, 4789.	3.7	18
174	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1015-1024.	0.8	18
175	PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Seminars in Nuclear Medicine, 2021, 51, 621-632.	4.6	17
176	Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers, 2022, 14, 1055.	3.7	17
177	Stateâ€ofâ€theâ€art imaging techniques in the management of preoperative staging and reâ€staging of prostate cancer. International Journal of Urology, 2019, 26, 18-30.	1.0	16
178	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 675-678.	5.0	16
179	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. European Urology Oncology, 2021, 4, 714-730.	5.4	16
180	Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant. Infection and Drug Resistance, 2021, Volume 14, 1185-1190.	2.7	16

#	Article	IF	Citations
181	Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. European Journal of Radiology, 2021, 141, 109793.	2.6	16
182	68Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, e415-e417.	1.9	15
183	11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT. Clinical Nuclear Medicine, 2013, 38, e279-e282.	1.3	14
184	11C-Meta-Hydroxyephedrine. Clinical Nuclear Medicine, 2015, 40, e96-e103.	1.3	14
185	²²³Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 104, 128-136.	1.1	14
186	Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. European Urology Oncology, 2023, 6, 41-48.	5.4	14
187	State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer. Archivos Espanoles De Urologia, 2015, 68, 354-70.	0.2	14
188	The detection of disease relapse after radical treatment for prostate cancer. Nuclear Medicine Communications, 2013, 34, 831-833.	1.1	13
189	Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Medical Imaging, 2021, 21, 49.	2.7	13
190	A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics, 2021, 11, 870.	2.6	13
191	Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. Molecular Imaging and Biology, 2013, 15, 194-202.	2.6	12
192	Imaging of Prostate Cancer Using 11 C-Choline PET/Computed Tomography. Urologic Clinics of North America, 2018, 45, 481-487.	1.8	12
193	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1908-1914.	6.4	12
194	PSMA-PET/CT imaging in prostate cancer: why and when. Clinical and Translational Imaging, 2019, 7, 377-379.	2.1	12
195	FDG-PET assessment and metabolic patterns in Lafora disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1576-1584.	6.4	12
196	Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 729-733.	1.0	11
197	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. Nuclear Medicine and Biology, 2015, 42, 858-863.	0.6	11
198	PET imaging in urology. Current Opinion in Urology, 2020, Publish Ahead of Print, 623-627.	1.8	11

#	Article	IF	Citations
199	Clinical aspects of mCRPC management in patients treated with radium-223. Scientific Reports, 2020, 10, 6681.	3.3	11
200	68Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 705-729.	1.5	11
201	Alternative and New Radiopharmaceutical Agents for Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 185-194.	0.8	11
202	PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clinics, 2007, 2, 351-375.	3.0	10
203	The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. Biomedicine and Pharmacotherapy, 2013, 67, 172-178.	5.6	10
204	Positron Emission Tomography With Computed Tomographyâ€“Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e101-e104.	0.4	10
205	FDG PET/CT for bone and soft-tissue biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1333-1334.	6.4	10
206	Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. Cancers, 2019, 11, 713.	3.7	10
207	The Role of Ultrasound in the Diagnosis of Soft Tissue Tumors. Seminars in Musculoskeletal Radiology, 2020, 24, 135-155.	0.7	10
208	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	5.0	10
209	Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 427-435.	6.4	10
210	Can Q.Clear reconstruction be used to improve [68ÂGa]Ga-DOTANOC PET/CT image quality in overweight NEN patients?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	6.4	10
211	PET/CT-Guided Biopsy of Suspected Lung Lesions Requires Less Rebiopsy Than CT-Guided Biopsy Due to Inconclusive Results. Journal of Nuclear Medicine, 2021, 62, 1057-1061.	5.0	10
212	Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation inÂFollicular Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 1695-1701.	2.0	9
213	68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. Clinical Nuclear Medicine, 2015, 40, e132-e133.	1.3	9
214	Identifying sites of recurrence with choline-PETâ€“CT imaging. Nature Reviews Urology, 2015, 12, 134-135.	3.8	9
215	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	6.4	9
216	Molecular Imaging and Precision Medicine in Prostate Cancer. PET Clinics, 2017, 12, 83-92.	3.0	9

#	Article	IF	Citations
217	Highlights of the 30th Annual Congress of the EANM, Vienna 2017: â€œYes we can â€“ make nuclear medicine great againâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1781-1794.	6.4	9
218	Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clinical Genitourinary Cancer, 2019, 17, 154-156.	1.9	9
219	Non-FDG PET/CT. Recent Results in Cancer Research, 2020, 216, 669-718.	1.8	9
220	New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms. Clinical Nuclear Medicine, 2022, 47, 219-220.	1.3	9
221	First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. Archivio Italiano Di Urologia Andrologia, 2014, 86, 239.	0.8	8
222	The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. Journal of Nuclear Medicine, 2017, 58, 1167-1173.	5.0	8
223	Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8
224	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncology, 2018, 14, 1101-1115.	2.4	8
225	Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma. Nuclear Medicine Communications, 2019, 40, 808-814.	1.1	8
226	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. European Urology, 2019, 75, 699-702.	1.9	8
227	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. Journal of Nuclear Cardiology, 2019, 26, 123-132.	2.1	8
228	Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. Cancers, 2020, 12, 659.	3.7	8
229	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3058-3065.	6.4	8
230	[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Research, 2020, 10, 122.	2.5	8
231	18F-Fdg-PET-guided Planning and Re-Planning (Adaptive) Radiotherapy in Head and Neck Cancer: Current State of Art. Anticancer Research, 2017, 37, 6523-6532.	1.1	8
232	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: Whatâ€™s Now, Whatâ€™s New, and Whatâ€™s Coming?. Cancers, 2022, 14, 907.	3.7	8
233	PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2103-2104.	6.4	7
234	The Possible Role of PET Imaging Toward Individualized Management ofÂBone and Soft Tissue Malignancies. PET Clinics, 2016, 11, 285-296.	3.0	7

#	Article	IF	Citations
235	Reliability of molecular imaging diagnostics. SynthÃˆse, 2019, , 1.	1.1	7
236	Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 999-1005.	5.0	7
237	Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. Journal of Nuclear Cardiology, 2022, 29, 1566-1575.	2.1	7
238	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 390-409.	6.4	7
239	Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). Diagnostics, 2021, 11, 1430.	2.6	7
240	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. World Journal of Clinical Cases, 2019, 7, 3018-3026.	0.8	7
241	Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. Cancers, 2022, 14, 1744.	3.7	7
242	18F-FDG PET/CT detects systemic involvement in sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2102-2102.	6.4	6
243	Of standard of reference and accuracy: the problem of truth in imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 52-54.	6.4	6
244	Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer. Nuclear Medicine Communications, 2020, 41, 411-415.	1.1	6
245	Prostate cancer: Molecular imaging and MRI. European Journal of Radiology, 2021, 143, 109893.	2.6	6
246	Rapidly growing pulmonary ground-glass nodule caused by metastatic melanoma lacking uptake on 18F-FDG PET-CT. Jornal Brasileiro De Pneumologia, 2018, 44, 171-172.	0.7	6
247	The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma. Seminars in Nuclear Medicine, 2021, , .	4.6	6
248	PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clinics, 2008, 3, 355-379.	3.0	5
249	FDG PET/CT in autoimmune pancreatitis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1264-1265.	6.4	5
250	Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. European Journal of Radiology, 2014, 83, 1301-1302.	2.6	5
251	PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. PET Clinics, 2015, 10, 487-494.	3.0	5
252	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs, 2016, 27, 353-363.	1.4	5

#	Article	IF	Citations
253	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRÎ± mutation in a metastatic GIST patient responding to imatinib. Scientific Reports, 2019, 9, 2172.	3.3	5
254	68Ga-PSMA-11 PET accuracy in recurrent prostate cancer. Translational Andrology and Urology, 2019, 8, 772-774.	1.4	5
255	Randomized Controlled Trials for Diagnostic Imaging: Conceptual and Pratical Problems. Topoi, 2019, 38, 395-400.	1.3	5
256	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. Clinical and Translational Imaging, 2021, 9, 215-220.	2.1	5
257	Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature. Minerva Urology and Nephrology, 2021, 73, 32-41.	2.5	5
258	The Impact of COVID-19 on Nuclear Medicine in Europe. Seminars in Nuclear Medicine, 2022, 52, 17-24.	4.6	5
259	¹¹C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. Current Radiopharmaceuticals, 2014, 7, 79-83.	0.8	5
260	ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo. Blood, 2008, 112, 4981-4981.	1.4	5
261	Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. Blood, 2012, 120, 3019-3019.	1.4	5
262	Performance of FDG PET/ceCT in the evaluation of patients with lung cancer. Biomedicine and Pharmacotherapy, 2014, 68, 219-223.	5.6	4
263	FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone. Clinical Nuclear Medicine, 2018, 43, e48-e49.	1.3	4
264	Standardisation of PSMA images interpretation: why do we need it?. Clinical and Translational Imaging, 2018, 6, 331-333.	2.1	4
265	Delivering PET imaging results to cancer patients: steps for handling ethical issues. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2240-2241.	6.4	4
266	Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. Leukemia and Lymphoma, 2019, 60, 2247-2254.	1.3	4
267	Single Subcutaneous Prostate Cancer Metastasis Detected by 68Ga-PSMA PET/CT During Early Biochemical Relapse: A Case Report. Clinical Genitourinary Cancer, 2019, 17, e356-e359.	1.9	4
268	Single-photon cardiac imaging in patients with cardiac implantable electrical devices. Journal of Nuclear Cardiology, 2022, 29, 633-641.	2.1	4
269	Optical coherence tomography assessment of macrophages accumulation in non-ST-segment elevation acute coronary syndromes. Journal of Cardiovascular Medicine, 2020, 21, 860-865.	1.5	4
270	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. Cancers, 2021, 13, 1575.	3.7	4

#	Article	IF	Citations
271	A novel tool for motion-related dose inaccuracies reduction in 99mTc-MAA SPECT/CT images for SIRT planning. Physica Medica, 2022, 98, 98-112.	0.7	4
272	Prediction of Overall Survival in Cervical Cancer Patients Using PET/CT Radiomic Features. Applied Sciences (Switzerland), 2022, 12, 5946.	2.5	4
273	Adrenocortical Positron Emission Tomography/PET-CT Imaging. PET Clinics, 2007, 2, 331-339.	3.0	3
274	Nuclear medicine in urological cancers: what is new?. Future Oncology, 2014, 10, 2061-2072.	2.4	3
275	Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2015, 56, 164-164.	5.0	3
276	Complete pathological response after chemo-radiation in anaplastic thyroid cancer: A report of two cases. Acta OncolÃ³gica, 2016, 55, 530-532.	1.8	3
277	A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. Clinical Genitourinary Cancer, 2017, 15, e525-e527.	1.9	3
278	Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3.	6.4	3
279	Incidental Detection of Basaloid Thymic Carcinoma With 68Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e497-e499.	1.9	3
280	Pictorial essay: normal variants, lesions, and pitfalls in 68Ga-PSMA PET imaging of prostate cancer. Clinical and Translational Imaging, 2018, 6, 239-247.	2.1	3
281	Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases. Clinical Genitourinary Cancer, 2019, 17, e612-e617.	1.9	3
282	68Ga-DOTANOC and 18F-DOPA PET/CT: a site-specific approach toÂthe imaging of parangliomas of theÂhead and neck Âand of theÂabdomen. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1393-1393.	6.4	3
283	Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. Cancers, 2019, 11, 1788.	3.7	3
284	Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 217-223.	6.4	3
285	Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time?. European Urology, 2020, 78, e125-e128.	1.9	3
286	Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors. Hepatobiliary Surgery and Nutrition, 2020, 9, 67-69.	1.5	3
287	Comments to â€œSurvey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CTâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2690-2691.	6.4	3
288	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clinical and Translational Imaging, 2021, 9, 423-438.	2.1	3

#	Article	IF	Citations
289	Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study. Current Radiopharmaceuticals, 2014, 7, 107-114.	0.8	3
290	Lung uptake detected by Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 300-306.	1.0	3
291	FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clinical and Translational Imaging, 2014, 2, 115-127.	2.1	2
292	Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161â€“75. European Urology, 2016, 70, e114-e115.	1.9	2
293	Molecular imaging and prostate cancer: unmet clinical needs and future perspectives. Clinical and Translational Imaging, 2016, 4, 421-422.	2.1	2
294	Imaging of Prostate Cancer Using 11 C-Choline PET/Computed Tomography. PET Clinics, 2017, 12, 137-143.	3.0	2
295	¹⁸F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. Journal of Thyroid Research, 2017, 2017, 1-9.	1.3	2
296	Phenotypic appearances of prostate utilizing PET-MRI and PET-CT with 68Ga-PSMA, radiolabelled choline and 68Ga-DOTATATE. Nuclear Medicine Communications, 2018, 39, 196-204.	1.1	2
297	HTA in nuclear medicine: [68Ga]PSMA PET/CT for patients with prostate cancer. Clinical and Translational Imaging, 2019, 7, 7-20.	2.1	2
298	68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2019, 44, 238-239.	1.3	2
299	Promise of PET imaging in prostate cancer. Current Opinion in Urology, 2020, 30, 9-16.	1.8	2
300	Contemporary Imaging Technologies for Men with Rising Prostate-specific Antigen After Radical Prostatectomy and Before Early Salvage Irradiation: Where Do We Stand?. European Urology Oncology, 2021, 4, 356-357.	5.4	2
301	Theranostics in oncology: What radiologists want to know. European Journal of Radiology, 2021, 142, 109875.	2.6	2
302	Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.. Blood, 2009, 114, 1659-1659.	1.4	2
303	The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?. Current Opinion in Urology, 2022, 32, 269-276.	1.8	2
304	Effects of Radiation Therapy and Chemotherapy on the Musculoskeletal System. Seminars in Musculoskeletal Radiology, 2022, 26, 338-353.	0.7	2
305	Preface. PET Clinics, 2007, 2, xi-xiii.	3.0	1
306	PET/CT in the Management and Prognosis of Pancreatic Exocrine Tumors. Clinical Nuclear Medicine, 2013, 38, 33-34.	1.3	1

#	Article	IF	Citations
307	PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications. Clinical and Translational Imaging, 2016, 4, 449-456.	2.1	1
308	The Wandering Mesenteric Lymph Node. Clinical Nuclear Medicine, 2017, 42, e253-e254.	1.3	1
309	What Is the Role of Imaging in Cancers?. Cancers, 2020, 12, 1494.	3.7	1
310	Long-Term Metabolic Assessment of Cryopreserved Sternal Allograft: A Case Series. Annals of Thoracic Surgery, 2021, 111, 1059-1063.	1.3	1
311	A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Untreated Follicular Lymphoma (FL) Patients.. Blood, 2009, 114, 3743-3743.	1.4	1
312	Fluoride PET/CT in Metastatic Benign Pulmonary Calcification. Nuklearmedizin - NuclearMedicine, 2018, 57, N50-N51.	0.7	1
313	Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?. European Urology Oncology, 2022, , .	5.4	1
314	EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3328-3329.	6.4	1
315	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	6.4	0
316	Radiopharmaceuticals in the evaluation and treatment of liver lesions. Clinical and Translational Imaging, 2014, 2, 99-101.	2.1	0
317	PET in natural killer/T-cell lymphoma: the debate continues. Lancet Haematology,the, 2015, 2, e50-e51.	4.6	0
318	Cholescintigraphic patterns in a IBS patient with postprandial diarrhea. Digestive and Liver Disease, 2018, 50, 720-721.	0.9	0
319	Atlas of PET-CT. , 2018, , .		0
320	Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their â€œLetter to the Editorâ€• Neuroendocrinology, 2019, 108, 366-366.	2.5	0
321	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. Applied Sciences (Switzerland), 2019, 9, 657.	2.5	0
322	Reply to â€œNo time like the present: time to rethink our habits in science and continuous medical education?â€• European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1630-1631.	6.4	0
323	Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System. Acta Haematologica, 2020, 143, 600-602.	1.4	0
324	18F-Choline, 68Ga-PSMA-11 and 18F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer. , 2021, , 261-295.		0

#	Article	IF	Citations
325	PET Imaging in Neuro-Endocrine Neoplasms (NEN). , 2021, , .		0
326	Calcification as a cause of potential false-positive findings in bone scintigraphy verified with [68Ga]Ga-PSMA-11 PET/CT - a case report. Polish Archives of Internal Medicine, 2021, 131, 473-475.	0.4	0
327	Radiological and Nuclear Medicine Imaging of Multiple Myeloma. , 2021, , .		0
328	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. Blood, 2005, 106, 3492-3492.	1.4	0
329	A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. Blood, 2009, 114, 2720-2720.	1.4	0
330	Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. Blood, 2013, 122, 5543-5543.	1.4	0
331	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	1.4	0
332	18F-FDG PET/CT for Bone and Soft Tissue Biopsy. , 2016, , 87-93.		0
333	New Radiopharmaceutical Markers for Metabolism and Receptor. , 2017, , 95-104.		0
334	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0
335	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775.		0
336	Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2018, , 1-15.		0
337	Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2019, , 125-139.		0
338	T Staging and Target Volume Definition by Imaging in GU Tumors. Medical Radiology, 2020, , 221-254.	0.1	0
339	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20â€‰ng/mL. Nuclear Medicine Communications, 2020, 41, 1178-1182.	1.1	0
340	The Philosophy of Advanced Medical Imaging: Mapping the Field. SpringerBriefs in Ethics, 2020, , 1-9.	0.6	0
341	Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study. Journal of Interventional Cardiac Electrophysiology, 2022, , .	1.3	0
342	Two birds with one stone: can [68Ga]Ga-DOTANOC PET/CT image quality be improved through BMI-adjusted injected activity without increasing acquisition times?. British Journal of Radiology, 2022, 95, 20211152.	2.2	0

#	Article	IF	Citations
343	Prostate cancer imaging and therapy. , 2018, , .		0